Campos Guilherme R F, Almeida Nathalie Bonatti Franco, Filgueiras Priscilla Soares, Corsini Camila Amormino, Gomes Sarah Vieira Contin, de Miranda Daniel Alvim Pena, de Assis Jéssica Vieira, de Souza Silva Thaís Bárbara, Alves Pedro Augusto, da Rocha Fernandes Gabriel, de Oliveira Jaquelline Germano, Rahal Paula, Grenfell Rafaella Fortini Queiroz, Nogueira Maurício L
Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.
Commun Med (Lond). 2022 Jun 29;2:76. doi: 10.1038/s43856-022-00141-4. eCollection 2022.
The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination.
Based on viral microneutralization assays, we evaluated in 90 individuals the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme.
Here we show that the percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 16.6% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times.
These results indicate a positive impact of this vaccine combination in the serological immune response against SARS-CoV-2 Omicron variant.
新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种的出现，与其他变种相比已知有大量突变，这引发了对疫苗逃逸的担忧，尤其是对疫苗诱导抗体中和作用的逃逸。
基于病毒微量中和试验，我们在90名个体中评估了科兴新冠疫苗（CoronaVac）初免方案后，一剂BNT162b2 mRNA疫苗加强针诱导针对奥密克戎变种抗体中和的影响。
我们在此表明，科兴新冠疫苗方案后30天和60天血清转化个体的百分比分别为16.6%和10%。加强针接种后，血清转化率升至76.6%。科兴新冠疫苗方案中针对奥密克戎的中和平均滴度随时间下降，但加强针接种后，平均滴度增加了43.1倍。
这些结果表明这种疫苗组合对针对SARS-CoV-2奥密克戎变种的血清学免疫反应有积极影响。
